Developing a biologic involves several interconnected processes, each capable of influencing product quality, yield and manufacturing consistency. Rebuilding these processes for every new molecule can extend development timelines and increase the experimental workload. Platform-based biologics development offers an alternative: establish a validated process framework that can be adapted across multiple products, reducing the need to solve the same manufacturing challenges repeatedly.

The approach is particularly relevant to monoclonal antibody (mAb) manufacturing, where established host-cell systems, culture methods and purification operations provide opportunities for process reuse. However, successful implementation depends on distinguishing which elements can be standardized and which require molecule-specific optimization.

Also read: Closing the Experimental Feedback Gap in AI-Driven Drug Discovery

Cell Line Development: Standardizing the Starting Point

Chinese hamster ovary (CHO) cells are widely used in therapeutic protein manufacturing because they support complex post-translational modifications, including glycosylation, which can influence biological activity and product quality.

Rather than developing an entirely new cell line workflow for every candidate, manufacturers can establish a common host-cell platform with standardized expression vectors, transfection methods, selection systems and clone-screening protocols.

Clone selection remains product-specific. Differences in protein structure, expression levels and cellular processing can affect productivity and critical quality attributes (CQAs). Consequently, each candidate requires evaluation for genetic stability, protein expression, growth characteristics and glycosylation profiles.

Standardizing the cell line development workflow makes the initial development stage more predictable without assuming that one production clone will suit every molecule.

Upstream Processing: Controlling Variables That Influence Product Quality

Upstream processing covers cell expansion and protein production in controlled bioreactor environments. Temperature, pH, dissolved oxygen, nutrient availability and feeding strategies influence cellular metabolism, productivity and the characteristics of the expressed protein.

Established upstream platforms provide reusable starting conditions for these parameters, supported by standardized seed-train procedures, basal media, feed formulations and bioreactor operating strategies.

Process analytical technologies (PAT) can strengthen these workflows by monitoring variables such as viable cell density, glucose consumption, lactate accumulation and dissolved oxygen. Such measurements help identify metabolic changes before they affect production performance or product quality.

However, identical operating conditions do not necessarily produce identical results across different cell lines or molecules. Process characterization must establish acceptable parameter ranges and identify interactions that influence CQAs, including glycosylation, charge variants and aggregation.

Downstream Processing: Reusing Purification Strategies

Downstream processing presents another opportunity for standardization, particularly in monoclonal antibody manufacturing. Many IgG antibodies share an Fc region that enables Protein A chromatography to serve as a common capture step.

A typical purification platform may include:

• Protein A chromatography: Captures the target antibody from clarified cell culture harvest
• Low-pH viral inactivation: Reduces the risk of viral contamination through a controlled inactivation step
• Polishing chromatography: Removes residual host-cell proteins, aggregates, DNA and other process-related impurities
• Virus filtration: Provides an additional viral clearance barrier
• Ultrafiltration and diafiltration: Concentrates the purified protein and exchanges the buffer into the desired formulation environment

Although the sequence of unit operations can often be reused, resin loading, buffer composition, pH, residence time and filtration conditions require evaluation. Differences in antibody aggregation, charge distribution and impurity profiles can affect purification performance.

Protein A-based workflows, for example, are not directly transferable to biologics without an appropriate Fc-binding mechanism. Complex modalities may require substantially different purification strategies.

Balancing Process Reuse With Product-Specific Requirements

Standardization has practical limits. A process that performs consistently for one monoclonal antibody may produce different quality attributes when applied to another. Bispecific antibodies, fusion proteins and other complex biologics can introduce additional challenges involving molecular heterogeneity, stability and impurity clearance.

Manufacturers must therefore establish product-specific CQAs, critical process parameters (CPPs) and appropriate analytical methods. When manufacturing processes change, comparability assessments are also important. ICH Q5E provides guidance for evaluating whether changes have adversely affected product quality, safety or efficacy.

Effective platform-based biologics development is ultimately a combination of established process knowledge and targeted experimentation. By standardizing repeatable operations while preserving flexibility at critical development stages, manufacturers can reduce unnecessary process redevelopment without compromising product quality or manufacturing control.